Solos Endoscopy, Inc. Receives Additional Purchase Orders from National Cancer Institute and National Institute of Health for its MammoView(TM) Product Line
BOSTON, Oct. 23 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company has received additional purchase orders for its MammoView(TM) line of surgical endoscopy instruments from the National Cancer Institute (NCI), as well as the U.S. National Institute of Health (NIOH), which is part of the U.S. Department of Health and Human Services. Solos Endoscopy's MammoView™ line of endoscopy surgical instruments has received positive reviews from various surgeons who have been regularly using the instruments during their endoscopic procedures.
NCI is 1 of 27 Institutes and Centers that comprise the U.S. National Institutes of Health. Located in Bethesda, Maryland, NIOH is the primary Federal agency for conducting and supporting medical research. Solos Endoscopy's MammoView(TM) system employs advanced micro endoscopes and optical technology to give physicians sharp, clear images of the milk ducts where the majority of breast cancers arise.
"The cytology retrieval kit which contains miniature brushes and a mini aspirator is, in my opinion, the best method for retrieving cell samples from the lining of the mammary duct," stated David N. Danforth Jr., M.S., M.D., Surgery Branch Senior Investigator from the National Institute of Health.
"We are very pleased to continue supplying our MammoView(TM) surgical endoscopy instruments to the top cancer care and research organizations in the country. We believe, as the body of research expands, more and more surgeons will utilize our system, which will enable them to detect possible cancerous cells in its early stage and begin treatments immediately on their patients," stated Bob Segersten, President of Solos Endoscopy, Inc.
Solos Endoscopy recently announced that the Company has taken the initial steps to get the CE Marking for its FDA approved MammoView™ line of surgical instruments. This will allow the MammoView(TM) line to be sold throughout the European Economic Union (EEU), which represents 30% or $94 Billion of the worldwide demand for medical instruments.
For more information on the National Cancer Institute, please visit: www.cancer.gov.
For more information on the National Institute of Health, please visit: www.nih.gov.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office with its catalog of FDA Approved products. Additional information is available on the Company's website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE Solos Endoscopy, Inc.